Skip to main content

Table 2 Description of TXA and transfusion treatment

From: The usefulness of tranexamic acid for bleeding symptoms of chronic consumptive coagulopathy complicated by aortic disease: a single-institute, retrospective study of 14 patients

 

n = 14

 

TXA duration, days, median (range, mean)

597

(6–2282, 776)

Initial TXA dose, mg/day, median (range, mean)

250

(50–1000, 314)

Final TXA dose, mg/kg/day, median (range, mean)

5.5

(2.3–15.0, 5.8)

Final TXA dose, mg/day, median (range, mean)

250

(150–500, 282)

PC or plasma derivative transfusion within 30 days post-TXA, n

6

 

 FFP

4

 

 Fibrinogen

1

 

 PC

3

 
  1. TXA Tranexamic acid, PC Platelet concentrate, FFP Fresh frozen plasma